Cracking the Code of Pain: A Biotech Alliance Targets Objective Measurement

PROVIDENCE, RI and DAYTON, OH – July 23, 2026 – For the estimated one in ten adults worldwide suffering from neuropathic pain, the diagnostic process often begins with a frustratingly simple question: “On a scale of one to ten, how much does it hurt?” For decades, this subjective scale has been the cornerstone of diagnosing and treating a condition born from nerve damage, a complex biological reality reduced to a single, patient-reported number. This reliance on subjective feeling over objective fact has created vast inconsistencies in care, but that may be about to change.

A strategic collaboration between a university-spinoff specializing in RNA technology and a clinical-stage neuromodulation company has produced a new framework that could finally bring objectivity to pain. In a joint clinical review published in Frontiers in Pain Research, Lilac Biosciences and Soin Neuroscience have outlined a roadmap for using RNA biomarkers to quantify neuropathic pain. This approach promises to move diagnostics from the patient’s perception to the molecular events driving their suffering, representing a potential paradigm shift in how millions are treated.

The Subjectivity Crisis in Pain Management

Neuropathic pain is not a simple sensation; it is a chronic disease of the somatosensory nervous system. It imposes a staggering burden, costing the U.S. economy alone over $600 billion annually in healthcare expenses and lost productivity. Yet the tools used to measure it—like the numerical rating scale or the brief pain inventory—are fundamentally subjective. Two patients with identical underlying pathology might report wildly different pain scores, leading to divergent treatment paths. This diagnostic ambiguity is a critical hurdle, with treatment response variability often exceeding 30%.

This “guesswork” approach has profound consequences. Incorrect diagnoses can lead to inappropriate treatments, including the over-prescription of opioids, while failing to capture the true efficacy of novel therapies. The lack of objective biomarkers makes it incredibly difficult for clinicians to stratify patients, predict their response to a specific drug or device, or monitor their progress over time with any degree of biological certainty. The industry has long sought a “pain-o-meter”—a reliable, biological measurement to guide clinical decisions. The answer, it seems, may not lie in a new device, but within the very molecular messengers that regulate our cells.

A Molecular Rosetta Stone: The Science of RNA Biomarkers

The collaboration’s proposed solution hinges on Ribonucleic acid, or RNA. While DNA is the stable blueprint of life, RNA is the dynamic workforce, translating genetic instructions into action. Changes in RNA expression and modification can provide a real-time snapshot of a cell's response to injury, disease, or treatment. This makes RNA an ideal candidate for a biomarker—a measurable indicator of a biological state.

The new review highlights several classes of RNA, but places particular emphasis on RNA modifications like N6-methyladenosine (m6A). This is the most common internal modification to RNA in our cells and acts as a crucial regulatory layer, influencing how, when, and where proteins are made. Crucially, these modifications are dynamic; they can be added or removed by enzymes in response to environmental signals. Research has shown that in neuropathic pain states, the patterns of m6A modifications are altered, influencing the signaling pathways that lead to central sensitization and chronic pain. By measuring these changes, scientists can develop a molecular signature, or a “pain biology score,” that correlates with the disease state.

"Pain is experienced subjectively, but it is driven by underlying molecular events," said Amol Soin, M.D., founder and CEO of Soin Neuroscience. "Identifying reproducible changes in RNA may give us an opportunity to measure and manage neuropathic pain with far greater precision."

This approach moves beyond simply measuring gene expression. It captures a more nuanced, functional layer of biology, potentially explaining why patients with similar genetics respond differently to pain. As Dr. Soin notes, these biomarkers could also provide “important insight into the mechanisms through which neuromodulation therapies produce pain relief,” opening the door to optimizing and personalizing such treatments.

A Blueprint for Innovation: The Power of Strategic Partnership

This potential breakthrough is not the product of a single lab but a testament to the power of interdisciplinary collaboration—a key driver of innovation in today’s complex biotech landscape. The partnership brings together two companies with perfectly complementary expertise.

Lilac Biosciences, a spin-out from the prestigious Giuliani RNA Center at Brown University, provides the deep technological capability. The Providence-based company specializes in building the next-generation tools needed to precisely measure RNA modifications, integrity, and quality. Their quantitative workflows are designed to bridge the gap between initial molecular insights and clinically relevant questions, turning complex RNA biology into reproducible data.

On the other side is Soin Neuroscience, a Dayton-based company founded by a practicing pain management physician. It is grounded in the clinical realities of treating chronic pain, developing novel neuromodulation technologies designed to offer non-narcotic relief. This clinical and engineering expertise ensures that the scientific research remains focused on a practical, deployable solution for real-world patient problems.

"Publishing this review with Dr. Soin and his team reflects Lilac's mission to translate RNA-based technologies into applied research and, ultimately, clinically meaningful tools," commented Shreyas Shah, vice president of business and commercial operations at Lilac Biosciences. "This collaboration brings together complementary scientific and clinical perspectives that can help advance the development of objective approaches to understanding and monitoring neuropathic pain."

The Roadmap from Lab to Clinic

The publication is not an announcement of a finished product but a foundational roadmap. The path from this theoretical framework to a routine clinical test is long and fraught with challenges. The proposed RNA signatures must first be rigorously validated in pre-clinical and large-scale human trials to prove their accuracy and reliability. Standardized methods for sample collection, processing, and analysis must be established to ensure results are consistent across different labs.

Furthermore, developing a research tool into a clinical diagnostic requires navigating the stringent regulatory pathways of agencies like the FDA, a process that demands extensive data on analytical and clinical validity. Currently, no RNA-based biomarkers are approved specifically for pain. Finally, the cost and accessibility of the underlying technologies, such as mass spectrometry and advanced sequencing, must be addressed for widespread adoption.

Despite these hurdles, the potential reward is transformative. The successful development of RNA biomarkers would usher in an era of precision medicine for neuropathic pain. Clinicians could use a simple blood test to diagnose a patient’s specific pain subtype, select the most effective therapy from the outset, and objectively monitor their response to treatment, adjusting as needed based on molecular feedback. This would not only improve patient outcomes but also dramatically accelerate the development of new pain therapies by providing clear, objective endpoints for clinical trials. The collaboration between Lilac Biosciences and Soin Neuroscience provides a powerful blueprint for how to tackle one of medicine’s most persistent challenges, moving it from the realm of subjective experience into the clear light of molecular science.